Clinical Trial Results:
A Phase 2, Randomized, Double-Blind, 4-week Crossover Trial to Investigate the Effect of a Once-Daily Combination of 500 μg Roflumilast Plus 10 mg Montelukast vs 10 mg Montelukast Alone on Pulmonary Function, Asthma Symptoms, and Inflammatory Markers in Subjects With Severe Asthma Not Adequately Controlled With a Combination of at Least Medium Dose Inhaled Corticosteroids and Long-Acting Beta Agonists Maintenance Therapy
Summary
|
|
EudraCT number |
2012-002064-27 |
Trial protocol |
DE HU |
Global end of trial date |
24 Oct 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Mar 2016
|
First version publication date |
05 Aug 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ROF-ASTHMA_202
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01765192 | ||
WHO universal trial number (UTN) |
U1111-1132-3160 | ||
Sponsors
|
|||
Sponsor organisation name |
Takeda Development Center Europe, Ltd.
|
||
Sponsor organisation address |
61 Aldwych, London, United Kingdom, WC2B 4AE
|
||
Public contact |
Medical Director , Takeda Development Center Europe, Ltd., +001 877-825-3327, trialdisclosures@takeda.com
|
||
Scientific contact |
Medical Director , Takeda Development Center Europe, Ltd., +001 877-825-3327, trialdisclosures@takeda.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Oct 2013
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
10 Oct 2013
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
24 Oct 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
|
||
Protection of trial subjects |
All study participants were required to read and sign an Informed Consent Form.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Feb 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 20
|
||
Country: Number of subjects enrolled |
Hungary: 17
|
||
Country: Number of subjects enrolled |
South Africa: 27
|
||
Worldwide total number of subjects |
64
|
||
EEA total number of subjects |
37
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
54
|
||
From 65 to 84 years |
10
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Participants took part in the study at 12 investigative sites in Germany, Hungary, and South Africa from 15 February 2013 to 24 October 2013. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Participants with a historical diagnosis of severe asthma who were inadequately controlled while receiving a combination of at least medium dose inhaled corticosteroids and long-acting beta agonists maintenance therapy were enrolled in 1 of 2 treatment sequences, 500 µg roflumilast plus 10 mg montelukast once daily (QD) or 10 mg montelukast QD. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Treatment period 1
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||
Blinding implementation details |
Blinding was maintained using the interactive voice response system (IVRS), which could be accessed by the investigator or designee in an emergency.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Roflumilast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Daxas, Daliresp
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
500 µg once daily (QD)
|
||||||||||||||||||
Investigational medicinal product name |
Montelukast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Singulair, Pluralair
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
10 mg once daily (QD)
|
||||||||||||||||||
Arm title
|
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Montelukast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Singulair, Pluralair
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
10 mg once daily (QD)
|
||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Placebo once daily (QD)
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Washout period
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
Arm title
|
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|||||||||||||||||||
Period 3
|
|||||||||||||||||||
Period 3 title |
Treatment period 2
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||
Blinding implementation details |
Blinding was maintained using the interactive voice response system (IVRS), which could be accessed by the investigator or designee in an emergency.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Montelukast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Singulair, Pluralair
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
10 mg once daily (QD)
|
||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Placebo once daily (QD)
|
||||||||||||||||||
Arm title
|
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Montelukast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Singulair, Pluralair
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
10 mg once daily (QD)
|
||||||||||||||||||
Investigational medicinal product name |
Roflumilast
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Daxas, Daliresp
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
500 µg once daily (QD)
|
||||||||||||||||||
|
|||||||||||||||||||
Period 4
|
|||||||||||||||||||
Period 4 title |
End of treatment period 2 to final visit
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
Arm title
|
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast | ||||||||||||||||||
Arm description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast
|
||
Reporting group description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast
|
||
Reporting group description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast
|
||
Reporting group description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast
|
||
Reporting group description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast
|
||
Reporting group description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast
|
||
Reporting group description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||
Reporting group title |
Roflumilast Plus Montelukast, Then Placebo Plus Montelukast
|
||
Reporting group description |
Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks | ||
Reporting group title |
Placebo Plus Montelukast, Then Roflumilast Plus Montelukast
|
||
Reporting group description |
Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks. | ||
Subject analysis set title |
Roflumilast Plus Montelukast
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Participants received roflumilast 500 μg plus montelukast 10 mg once daily for 4 weeks.
|
||
Subject analysis set title |
Placebo Plus Montelukast
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Participants received placebo plus montelukast 10 mg once daily for 4 weeks.
|
|
|||||||||||||
End point title |
Change From Baseline in Pre-dose (Trough) Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | ||||||||||||
End point description |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 will be measured using spirometry in accordance with the American Thoracic Society / European Respiratory Society (ATS/ERS) consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEV1 measurement as the covariate was used for analysis.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in FEV1 | ||||||||||||
Statistical analysis description |
The primary endpoint was analyzed using an analysis of covariance model adapted for the crossover design. The following fixed factors and covariates were included in the model: Treatment, sequence, period, and baseline FEV1 measurement of the respective treatment period. The reported analysis results are for the 2 crossover treatment periods combined.
|
||||||||||||
Comparison groups |
Placebo Plus Montelukast v Roflumilast Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
119
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.013 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Least squares (LS) mean difference | ||||||||||||
Point estimate |
0.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.0219 | ||||||||||||
upper limit |
0.1795 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.039
|
|
|||||||||||||
End point title |
Change From Baseline in Pre-dose (Trough) Pre-bronchodilator Forced Vital Capacity (FVC) | ||||||||||||
End point description |
FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline to Week 4 in FVC | ||||||||||||
Statistical analysis description |
An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.
|
||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
119
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.129 [1] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean Difference | ||||||||||||
Point estimate |
0.06
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.0185 | ||||||||||||
upper limit |
0.1422 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.04
|
||||||||||||
Notes [1] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator FVC measurement as the covariate. |
|
|||||||||||||
End point title |
Change From Baseline in Pre-dose (Trough) Pre-bronchodilator Forced Expiratory Flow (FEF) 25-75% | ||||||||||||
End point description |
FEF is a measure of how much air can be exhaled from the lungs. It is an indicator of obstruction of the smaller airways. FEF25-75% is the mid-flow rate or forced expiratory flow occurring in the middle 50% of the patient's exhaled volume, and will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEF measurement as the covariate was used for analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in FEF | ||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
109
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.032 [2] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean difference | ||||||||||||
Point estimate |
0.12
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.0113 | ||||||||||||
upper limit |
0.2364 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.056
|
||||||||||||
Notes [2] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator FEF measurement as the covariate. |
|
|||||||||||||
End point title |
Change From Baseline in Pre-dose (Trough) Pre-bronchodilator Peak Expiratory Flow (PEF) | ||||||||||||
End point description |
PEF is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. PEF will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in PEF | ||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
119
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.635 [3] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean difference | ||||||||||||
Point estimate |
7.21
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-23.0531 | ||||||||||||
upper limit |
37.466 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
15.105
|
||||||||||||
Notes [3] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator PEF measurement as the covariate. |
|
|||||||||||||
End point title |
Change From Baseline in Morning Peak Expiratory Flow (PEF) | ||||||||||||
End point description |
PEF will be measured at home using portable electronic peak flow meter. The participant will record PEF daily in the morning immediately after getting up. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in Morning PEF | ||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
121
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.011 [4] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean difference | ||||||||||||
Point estimate |
13.62
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
3.1896 | ||||||||||||
upper limit |
24.0553 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
5.206
|
||||||||||||
Notes [4] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator PEF measurement as the covariate. |
|
|||||||||||||
End point title |
Change From Baseline in Daytime Asthma Symptoms | ||||||||||||
End point description |
Patients will assess their daily day-time asthma symptoms according to the following scale:
0: Very well, no symptoms.
1: One episode of wheezing, cough, or breathlessness.
2: More than 1 episode of wheezing, cough, or breathlessness without interference with normal activities.
3: Wheezing, cough, or short of breath most of the day which interfered to some extent with normal activities.
4: Asthma very bad. Unable to carry out daily activities, as usual.
An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in Daytime Asthma Symptoms | ||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
121
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.025 [5] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean difference | ||||||||||||
Point estimate |
-0.21
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.385 | ||||||||||||
upper limit |
-0.0271 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.089
|
||||||||||||
Notes [5] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptom Score as the covariate. |
|
|||||||||||||
End point title |
Change From Baseline in Nighttime Asthma Symptoms | ||||||||||||
End point description |
Patients will assess their daily night-time asthma symptoms according to the following scale:
0: No symptoms, slept through the night.
1: Slept well but some complaints in the morning.
2: Woke up once because of asthma (inclusive early awakening).
3: Woke up several times because of asthma (inclusive early awakening).
4: Bad night, awake most of the night because of asthma.
An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change from Baseline in Nighttime Asthma | ||||||||||||
Comparison groups |
Roflumilast Plus Montelukast v Placebo Plus Montelukast
|
||||||||||||
Number of subjects included in analysis |
121
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.217 [6] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS Mean difference | ||||||||||||
Point estimate |
-0.09
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.2426 | ||||||||||||
upper limit |
0.0563 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.075
|
||||||||||||
Notes [6] - P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate. |
|
||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline to the end of the study (Days 1-105)
|
|||||||||||||||||||||
Adverse event reporting additional description |
Safety analysis set: All randomized participants who received at least 1 dose of study drug.
Adverse events are reported for 61 and 62 participants in the roflumilast + montelukast (R+M) and placebo + montelukast (P+M) treatment groups, respectively, as 3 participants discontinued prior to receiving R+M and 2 participants discontinued prior to rec
|
|||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||
Dictionary version |
16.0
|
|||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||
Reporting group title |
Roflumilast Plus Montelukast
|
|||||||||||||||||||||
Reporting group description |
Participants received roflumilast 500 μg plus montelukast 10 mg once daily for 4 weeks. | |||||||||||||||||||||
Reporting group title |
Placebo Plus Montelukast
|
|||||||||||||||||||||
Reporting group description |
Participants received placebo plus montelukast 10 mg once daily for 4 weeks. | |||||||||||||||||||||
|
||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |